Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection
Aditxt subsidiary Ignite Proteomics launched a prospective oncology registry enrolling up to 10,000 patients to evaluate functional proteomics in cancer therapy selection. The initiative pairs Ignite’s CLIA-certified RPPA platform with structured outcomes tracking across ADC and immunotherapy regimens, with enrollment expected to begin in fall 2026.
Key figures
- Proteins measured
- 32+
- Estimated revenue usd
- 13000000
- Registry patient count
- 10000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.